Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria

Documenti analoghi

• Early reduction in albuminuria is associated with a steeper ‘dip’ in initial estimated glomerular filtration rate but favourable long‐term kidney outcomes in people with diabetes receiving sodium‐glucose cotransporter‐2 inhibitors
  di: Yi‐Wei Kao, et al.
  Pubblicazione: (2024)
• Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
  di: Yuri Sakai Ishizaki, et al.
  Pubblicazione: (2024)
• Sodium‐glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real‐world case series
  di: Anthea Tsatsaronis, et al.
  Pubblicazione: (2024)
• Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome
  di: Chunxiang Xu, et al.
  Pubblicazione: (2025)
• The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
  di: Leonardo Buttice, et al.
  Pubblicazione: (2024)